Application of Nomilin and composition containing it

By using nomilin and its compositions, the problem of lack of effective anti-aging compounds in the prior art is solved, extending life, improving mobility and detoxification ability, and delaying aging, and has significant research and clinical potential.

CN116265018BActive Publication Date: 2024-11-15SHANGHAI UNIV OF T C M
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310078223.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-16
Publication Date
2024-11-15
Estimated Expiration
2043-01-16

AI Technical Summary

Technical Problem

The prior art lacks effective anti-aging compounds, which cannot effectively delay the aging process and improve the body's function.

Method used

Using nomilin and its compositions, the aging symptoms are delayed by preparing anti-aging drugs, health foods or animal feed, including pharmaceutical carriers and food additives.

Benefits of technology

It has significant research value and clinical application potential to extend the lifespan of nematodes, improve mobility, reduce lipofuscin deposition, enhance stress and detoxification ability, and delay mice aging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116265018B_ABST
    Figure CN116265018B_ABST
Patent Text Reader

Abstract

The present invention discloses a kind of application of Nomilin and a composition containing the same. The Nomilin is shown in the following formula, and the composition further comprises a pharmaceutically acceptable carrier and / or excipient, or a food additive. The Nomilin of the present invention prolongs the life span of nematodes (including average life span and maximum life span), improves the activity of nematodes, reduces the deposition of lipofuscin caused by aging, and improves stress resistance and detoxification ability; in addition, it delays the aging and body function degradation of mice, increases stress resistance and detoxification ability, and has great research value and clinical application potential. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and specifically relates to the application of nomilin and a composition containing the nomilin. Background Art

[0002] Aging is an inevitable trend in the development and existence of living things. It mainly refers to a series of systemic and multifaceted degenerative changes in the body's morphology, structure, and physiological functions that occur after the human body grows to maturity and ages. Aging is not only a determining factor in human life span, but also a major risk factor for many age-related diseases, such as cancer, cardiovascular disease, and diabetes. At present, there are no anti-aging drugs that can be applied to humans. Therefore, the research on anti-aging drugs is increasingly attracting attention from countries around the world.

[0003] Nomilin belongs to the limonoid compound class and is a plant secondary metabolite of triterpenes. It is mainly found in plants of the Rutaceae and Meliaceae families, and is especially abundant in the seeds and peels of citrus. Studies in recent years have shown that Nomilin has a variety of pharmacological effects, including tumor inhibition, anti-inflammatory, and antioxidant effects. Summary of the invention

[0004] The technical problem to be solved by the present invention is to overcome the defect of the prior art that there is a lack of effective anti-aging compounds, and to provide an application of Nomilin and a composition containing the same. Nomilin (CAS No.: 1063-77-0) of the present invention prolongs the life span of nematodes (including average life span and maximum life span), improves the activity of nematodes, reduces the deposition of lipofuscin caused by aging, and improves stress resistance and detoxification ability; in addition, it delays the aging and body function degeneration of mice, and increases stress and detoxification ability.

[0005] The present invention solves the above technical problems through the following technical solutions.

[0006] The first aspect of the present invention provides a use of a compound as shown in the following formula or a composition containing the compound in the preparation of an anti-aging drug, a common food or a health food for delaying aging;

[0007]

[0008] The composition further comprises a pharmaceutically acceptable carrier and / or auxiliary material, or a food additive.

[0009] In the present invention, when preparing a drug, the composition comprises the compound shown in the above formula and a pharmaceutically acceptable carrier and / or excipient; when preparing ordinary food, health food or animal feed, the composition comprises the compound shown in the above formula and a food additive.

[0010] In the present invention, in the composition, the content of the compound is 20-150 μM, preferably 25-120 μM, and more preferably 50-100 μM.

[0011] In some specific embodiments of the present invention, the content of the compound is, for example, 20 μM, 25 μM, 30 μM, 35 μM, 40 μM, 45 μM, 50 μM, 55 μM, 60 μM, 65 μM, 70 μM, 75 μM, 80 μM, 85 μM, 90 μM, 95 μM, 100 μM, 105 μM, 110 μM, 115 μM, 120 μM, 125 μM, 130 μM, 135 μM, 140 μM, 145 μM or 150 μM.

[0012] In some embodiments of the present invention, the symptoms of aging are selected from shortened lifespan, decreased mobility, increased lipofuscin deposition, degenerative changes in the heart, liver and brain, decreased liver resistance to oxidative stress and decreased detoxification capacity.

[0013] The second aspect of the present invention provides a use of a compound as shown in the following formula or a composition containing the compound in the preparation of an insulin / IGF-1 signaling pathway activator;

[0014]

[0015] The composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0016] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0017] The third aspect of the present invention provides a use of a compound as shown in the following formula or a composition containing the compound in the preparation of a drug for improving stress resistance:

[0018]

[0019] The composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0020] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0021] In some embodiments of the present invention, the stress capacity is selected from heat stress capacity and oxidative stress capacity.

[0022] In some specific embodiments of the present invention, the heat stress is 35°C acute heat stress.

[0023] In some specific embodiments of the present invention, the oxidative stress is oxidative stress caused by 0.5‰ hydrogen peroxide.

[0024] The fourth aspect of the present invention provides a use of a compound as shown in the following formula or a composition containing the compound in the preparation of a drug for resisting toxic substances, a common food or a health food for weakening the effects of toxic substances;

[0025]

[0026] The composition further comprises a pharmaceutically acceptable carrier and / or auxiliary material, or a food additive.

[0027] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0028] In some embodiments of the present invention, the toxic substance is a substance that has a destructive effect on the life activities of normal organisms.

[0029] The toxic substance may be conventional in the art, such as a chlorine-containing compound.

[0030] In some specific embodiments of the present invention, the toxic substance is selected from chloroquine, colchicine, paraquat dichloride and methylmercury chloride.

[0031] The fifth aspect of the present invention provides a use of a compound as shown in the following formula or a composition containing the compound in the preparation of a DAF-16 nuclear transfer accelerator;

[0032]

[0033] The composition further comprises a pharmaceutically acceptable carrier and / or excipient;

[0034] The DAF-16 nuclear transfer promoter promotes the nuclear transfer of DAF-16 and increases the transcriptional activity of DAF-16, thereby regulating the expression of DAF-16 downstream genes.

[0035] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0036] The sixth aspect of the present invention provides a compound as shown in the following formula or a composition containing the compound for use in preparing a drug or animal feed for delaying degenerative changes in the heart, liver and brain of mice, and enhancing the liver's ability to resist oxidative stress, detoxify and exercise;

[0037]

[0038] The composition further comprises a pharmaceutically acceptable carrier and / or auxiliary material, or a food additive.

[0039] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0040] In some embodiments of the present invention, the mouse is a D-galactose-induced aging mouse.

[0041] The seventh aspect of the present invention provides a method for alleviating the symptoms of aging, the method comprising administering to a subject in need thereof an effective amount of a compound represented by the following formula or a composition containing the same;

[0042]

[0043] The composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0044] In some embodiments of the present invention, the symptoms of aging are as described in the first aspect.

[0045] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0046] The eighth aspect of the present invention provides a method for improving stress resistance, the method comprising administering to a subject in need thereof an effective amount of a compound represented by the following formula or a composition containing the same;

[0047]

[0048] The composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0049] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0050] In some embodiments of the present invention, the stress response ability is as described in the third aspect.

[0051] The ninth aspect of the present invention provides a method for resisting toxic substances, the method comprising administering to a subject in need thereof an effective amount of a compound represented by the following formula or a composition containing the same;

[0052]

[0053] The composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0054] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0055] In some embodiments of the present invention, the toxic substance is as described in the fourth aspect.

[0056] The tenth aspect of the present invention provides a method for delaying degenerative changes in the heart, liver and brain of mice, and enhancing the liver's ability to resist oxidative stress, detoxify and exercise, the method comprising administering to the mice an effective amount of a compound or a composition containing the compound as shown in the following formula:

[0057]

[0058] The composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0059] In some embodiments of the present invention, the content of the compound in the composition is as described in the first aspect.

[0060] In some embodiments of the present invention, the mouse is as described in the sixth aspect.

[0061] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0062] The reagents and raw materials used in the present invention are commercially available.

[0063] The positive and progressive effects of the present invention are:

[0064] The Nomilin of the present invention prolongs the life span of nematodes (including average life span and maximum life span), improves the activity of nematodes, reduces the deposition of lipofuscin caused by aging, and improves stress resistance and detoxification capabilities; in addition, it delays aging and body function degradation of mice, increases stress and detoxification capabilities, and has great research value and clinical application potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 Schematic diagram of the effect of nomilin on the lifespan of N2 nematodes.

[0066] Figure 2 Schematic diagram of the effect of nomilin on the nematode swallowing ability 5 days after administration.

[0067] Figure 3 This is a schematic diagram showing the effect of Nomilin on the nematode swallowing ability after 10 days of administration.

[0068] Figure 4 Schematic diagram of the effect of nomilin on the head swing frequency of nematodes.

[0069] Figure 5 Schematic diagram of the effect of nomilin on the body bending frequency of nematodes.

[0070] Figure 6 Schematic diagram of the effect of nomilin on lipofuscin deposition in 10-day-old nematodes;

[0071] Among them, a is the fluorescence image and b is the data statistics graph.

[0072] Figure 7 Schematic diagram of the effect of Nomilin on nematodes' resistance to heat stress (35°C).

[0073] Figure 8Schematic diagram of the effect of nomilin on the nematode's ability to resist oxidative stress (H2O2).

[0074] Fig. 9 Schematic diagram of the effect of nomilin on the lifespan of daf-2 mutant nematodes.

[0075] Fig.10 Schematic diagram of the effect of nomilin on the lifespan of daf-16 mutant nematodes.

[0076] Fig.11 Schematic diagram of the effect of normilin on the nuclear localization of DAF-16;

[0077] Among them, a is the fluorescence image and b is the data statistics graph.

[0078] Fig.12 Schematic diagram of the nematode resistance experiment to chloroquine (a, b) and colchicine (c, d) after the administration of nomiline.

[0079] Fig.13 Schematic diagram of the nematode resistance experiment to paraquat dichloride (a, b) and methylmercury chloride (c, d) after administration of nomiline.

[0080] Fig.14 Schematic diagram of the effect of nomilin on D-galactose-induced liver inflammation in premature aging mice.

[0081] Fig.15 Schematic diagram of the effect of nomilin on neuronal death in the brain tissue of D-galactose-induced premature aging mice.

[0082] Fig.16 Schematic diagram of the effect of Nomilin on the motor ability of D-galactose-induced premature aging mice;

[0083] Among them, A is the time to climb down from the pole, and B is the time to pass through the balance beam.

[0084] Fig.17 Schematic diagram of the effect of nomilin on the expression of liver detoxification genes in D-galactose-induced premature aging mice.

[0085] Fig.18 Schematic diagram of the effect of nomilin on the expression of liver inflammation and oxidative stress genes in D-galactose-induced premature aging mice. DETAILED DESCRIPTION

[0086] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0087] The method used in the embodiment is as follows:

[0088] 1. Nematode lifespan experiment: The synchronized N2 nematodes and daf-2 and daf-16 homologous gene knockout mutant nematodes were cultured to the L4 stage, and then DMSO, 25, 50, and 100 μM nomilin (hereinafter referred to as NML) were given respectively to observe the effect of NML on the lifespan of nematodes and to determine the NML dose with the best life-extending effect.

[0089] 2. Evaluate the effect of NML on physiological indicators related to lifespan of nematodes: Use a stereomicroscope to observe and record the swallowing frequency, head swinging frequency, body bending frequency and lipofuscin deposition of nematodes in the control group and each NML treatment group.

[0090] 3. Stress experiment: To investigate the effect of NML administration on the lifespan of nematodes under conditions of acute heat stress at 35°C and oxidative stress caused by 0.5% hydrogen peroxide.

[0091] 4. DAF-16 nuclear translocation experiment: daf-16P::daf-16::GFP mutant nematodes were selected, and the nuclear translocation of DAF-16 in the control group and the NML-treated group was observed under a laser scanning confocal microscope.

[0092] 5. Toxicity experiment: After administering the exogenous compounds chloroquine, colchicine, paraquat dichloride and methylmercuric chloride to the control group and the NML-administered group N2 nematodes, the survival status of the nematodes in each group was observed and the survival time was recorded.

[0093] 6. Healthy life span of D-galactose-induced aged mice: Using the D-galactose-induced aged mouse model, the in vivo efficacy of nomilin was evaluated by observing the effects of nomilin on aging indicators of aged mice, H&E staining of the liver and hippocampus of mice, and pathological damage scores.

[0094] Example 1: Nematode lifespan experiment

[0095] 1.1. Synchronization of nematodes

[0096] Select nematodes in the egg-laying stage, use M9 buffer (3g potassium dihydrogen phosphate, 6g disodium hydrogen phosphate, 5g sodium chloride, 1L distilled water, 121℃ autoclave, after cooling, add 1mL 1mol / L magnesium sulfate solution under aseptic conditions) to collect the worm body and eggs in a 50mL centrifuge tube, when the final volume of the collection liquid reaches 5mL, add 2.134mL prepared nematode lysis solution (5mol / L sodium hydroxide (sterilized) 1mL and 5% sodium hypochlorite 2mL fully mixed), vortex 4-5min until the worm body is completely lysed. Add M9 buffer to make the collection liquid volume 50mL, centrifuge at 2900rmp for 1min, discard the supernatant, repeat 4 times, finally add 5mL M9 buffer to the centrifuge tube, resuspend the precipitate, place the centrifuge tube in a 20℃ biochemical incubator for 12h, and obtain L1 stage larvae. Use a pipette to transfer the larvae into an NGM culture dish (17.5 g agar powder, 3 g sodium chloride, 2.5 peptone, add 975 mL distilled water, sterilize at 121°C, cool to about 60°C, and add the following sterilized solutions in sequence under sterile conditions: 1 mL 1 mol / L magnesium sulfate solution, 25 mL 1 mol / L potassium phosphate buffer, 1 mL 5 mg / mL cholesterol solution, and 1 mL 1 mol / L calcium chloride solution. After fully mixing on a constant magnetic stirrer, use a pipette to dispense into a plate to make an NGM agar plate, which is stored at 4°C for later use.) and cultured in a 20°C biochemical incubator for subsequent experiments.

[0097] 1.2. Nematode lifespan experiment

[0098] 1. Experimental groups: The nematodes were divided into a DMSO (purchased from Sigma-Aldrich) control group and low, medium and high doses (25, 50 and 100 μM, respectively) of NML (purchased from Carlead Biopharmaceutical Technology (Shanghai) Co., Ltd., CAS#1063-770) administration groups (hereinafter referred to as NML25, NML50 and NML100, respectively).

[0099] 2. Preparation of OP50 bacterial solution in each experimental group: DMSO and NML stock solutions with concentrations of 25, 50 and 100 mM / L (5.146 mg NML powder was weighed and dissolved in 100 μL DMSO solvent to prepare a solution with a concentration of 100 mmol / L (high dose), and then diluted with DMSO in an equal volume ratio to 50 mmol / L (medium dose) and 25 mmol / L (low dose) NML solutions, and stored in a 4°C refrigerator away from light for later use) were added to the OP50 bacterial solution at a volume ratio of 1:1000, so that the final concentration of the diluted drug was 25, 50 and 100 μM / L.

[0100] 3. Lifespan experiment: The nematodes cultured to the L4 stage after synchronization were transferred to solid NGM culture dishes paved with OP50 plus DMSO or low, medium, and high doses of NML, and then the culture dishes were inverted in a 20°C biochemical incubator (purchased from Zhicheng Analytical Instrument Manufacturing Co., Ltd.) for culture. During the egg-laying period (i.e., the first 5-6 days of the lifespan experiment), the nematodes must be moved to a new culture dish every day; after the egg-laying period, the surviving nematodes were moved to a new culture dish every 1 day, and the survival status of each group of nematodes was observed, and the number of deaths was recorded until all the nematodes died. The criterion for determining the death of nematodes: There was no reaction when the worm body was lightly touched with a platinum pick. If the adult worms crawled to the wall or cover of the culture dish and died, burrowed into the culture medium and lost, or the eggs hatched in the worm body, resulting in the death of the adult worms, the number of these dead worms was not counted in the total number. The lifespan experiment was repeated three times, and the average value of the three experiments was taken for result analysis.

[0101] The experimental results of the effect of NML on the life span of wild-type (N2) nematodes (purchased from the National Bioresource Project of Japan) showed that NML25, NML50 and NML100 could shift the survival curve of N2 nematodes to the right and significantly extend the life span of N2 nematodes ( Figure 1 The average survival time of N2 nematodes in NML25, NML50 and NML100 groups were (17.84±0.35d), (20.28±0.42d) and (20.16±0.42d), respectively, which were 9.43% (p<0.01), 24.38% (p<0.001) and 23.65% (p<0.001) longer than that in DMSO group (16.30±0.34d), respectively; the median survival time was extended from 15d to 17d, 19d and 19d, respectively (Table 1).

[0102] Table 1: Effects of NML on the life span of N2 nematodes

[0103] Group Number of insects Average life span (days) Maximum lifespan (days) Median survival time (days) Extended life span percentage DMSO 172 16.30±0.34 25 15 - NML25 168 17.84±0.35** 29 17 9.43% NML50 166 20.28±0.42*** 34 19 24.38% NML100 159 20.16±0.42*** 33 19 23.65%

[0104] Note: The results are expressed as mean ± standard error, N represents the number of samples in each group; compared with the control group (DMSO), ** represents p < 0.01, *** represents p < 0.001.

[0105] Example 2: Determination of physiological indicators related to aging in nematodes

[0106] Effects of NML on the nematode swallowing ability

[0107] N2 nematodes were selected from the L4 stage after synchronization and were administered for 5 and 10 days. There were 10 nematodes in each of the DMSO control group and the low, medium and high dose NML administration groups. One nematode was observed at a time under a stereo microscope (purchased from Motic Industrial Group Co., Ltd.) and the number of pharyngeal pumps per minute was counted. The experiment was repeated three times. The results showed that the swallowing frequency of nematodes decreased with age. However, after 5 days of NML administration (see Figure 2 ) and 10 days (see Figure 3 ) can significantly enhance the swallowing frequency of nematodes which decreases with aging.

[0108] 2.2. Effect of NML on the head shaking frequency of nematodes

[0109] Select N2 nematodes that were synchronized and dosed from the L4 stage for 10 days, and select 10 nematodes each from the DMSO control group and the low, medium, and high dose NML treatment groups. First transfer the nematodes to a blank NGM culture medium, wait for them to detach from the OP50 adhering to their bodies after movement, and then transfer them to another blank NGM culture dish. Track one nematode at a time under a stereomicroscope for one minute, and record the number of head swings within one minute. A head swing is defined as the process of the nematode's head swinging from one direction to another and then swinging back. The experiment was repeated three times. Figure 4 It can be seen that the head swing frequency of nematodes decreases with age, while NML can significantly enhance the head swing frequency of nematodes that decreases with aging.

[0110] Effect of NML on the frequency of body bending in C. elegans

[0111] N2 nematodes that were synchronized and dosed for 10 days from the L4 stage were selected, and 10 nematodes were included in each of the DMSO control group and the low, medium, and high dose NML treatment groups. The nematodes were first transferred to a blank NGM culture medium, and after they moved and detached from the OP50 adhering to their bodies, they were transferred to another blank NGM culture dish. Each nematode was tracked under a stereomicroscope for 20 seconds at a time, and the number of body bends of the nematode within 20 seconds was recorded. The distance that the nematode moved relative to one wavelength in the direction of the long axis of the body was defined as one body bend. The experiment was repeated three times. Figure 5 It can be seen that the body bending frequency of nematodes decreases with age, while NML can significantly enhance the body bending frequency of nematodes that decreases with aging.

[0112] Effects of NML on lipofuscin deposition in nematodes

[0113] Under a fluorescence microscope (purchased from Carl Zeiss AG), the degree of aging can be judged based on the fluorescence intensity of lipofuscin observed in the intestine of the nematode. Operation method: Add a drop of pre-heated 2% agar solution on the slide, cover it vertically with another slide, remove bubbles, and flatten the agar. After the agar cools and solidifies, remove the upper slide, add a drop of 0.2% sodium azide (NaN3) in the center of the agar, synchronize the DMSO control group and the low, medium, and high doses of NML treatment groups, and pick the N2 nematodes that were treated for 10 days from the L4 stage into the NaN3 droplet, cover with a coverslip, observe and photograph under a fluorescence microscope. Use ImageProPlus6.0 (IPP6.0) software to analyze the fluorescence intensity in the nematodes. The experiment was repeated three times. The results showed that NML can also significantly reduce the deposition of lipofuscin caused by aging in wild-type nematodes ( Figure 6 ).

[0114] Effects of NML on nematode resistance to heat stress

[0115] Referring to the acute heat stress experimental method of Wilson et al. (Wilson MA, Shukitt-Hale B, Kalt W. Blueberry polyphenols increase lifespan and thermotolerance in Caenorhabditis elegans. Aging Cell. 2006, 5 (1): 59-68), N2 nematodes were selected and administered for 10 days from the L4 stage after synchronization, and 30 nematodes were selected from the DMSO control group, NML25, 50 and 100 μM / L administration groups. The nematodes were selected into a blank NGM culture dish, and the culture dish was inverted in a 35°C biochemical incubator. The time of placement was recorded as 0 o'clock, and then the culture dish was taken out every 2 hours within 12 hours, observed under a stereomicroscope, the number of dead nematodes was recorded, and the dead nematodes were picked out from the dish. The criterion for judging the death of nematodes was the same as that of the lifespan experiment. The experiment was repeated three times. Figure 7 The results showed that NML could prolong the survival time of nematodes under acute heat stress conditions at 35°C and increase their resistance to heat shock.

[0116] Effects of NML on the antioxidant capacity of nematodes

[0117] Referring to the acute oxidative stress experimental method of Duhon et al. (Duhon SA, Murakami S, Johnson TE. Direct isolation of longevity mutants in the nematode Caenorhabditis elegans. Dev Genet. 1996, 18 (2): 144-153), N2 nematodes were selected and administered for 10 days from the L4 stage after synchronization, and 30 nematodes were selected from the DMSO control group, 25, 50 and 100 μM / L NML administration groups. The nematodes were selected into the NGM culture dish containing 0.5‰ H2O2, and the culture dish was inverted in a 20°C biochemical incubator. The time of placement was recorded as 0 o'clock, and then the culture dish was taken out every 2 hours within 12 hours, observed under a stereomicroscope, the number of dead nematodes was recorded, and the dead nematodes were picked out from the dish. The criterion for judging the death of nematodes was the same as that for the lifespan experiment. The experiment was repeated three times. Figure 8 The results showed that NML could prolong the survival time of nematodes under oxidative stress conditions caused by 0.5‰ hydrogen peroxide and increase the resistance of nematodes to oxidative stress.

[0118] Example 3: Study on the potential life extension mechanism of NML - Effects of NML Nomilin on the IIS pathway of nematodes

[0119] Effects of NML on the lifespan of daf-2 mutant nematodes

[0120] To explore the potential life extension mechanism of NML, DMSO, NML25, NML50 and NML100 were given to synchronized L4 stage daf-2 mutant nematodes (purchased from the National Bioresource Project of Japan), and then life span experiments were performed. The method of life span experiment was the same as that in Example 1. The experimental results showed that the average survival period of daf-2 nematodes in the DMSO control group (42.9±0.8d) was significantly longer than that of N2 nematodes (16.3±0.3d), and the maximum survival period (62d) and median survival period (45d) were significantly longer than those of N2 nematodes (25d and 15d) (Table 2 and Table 1), indicating that the mutant model is stable. The average survival time of daf-2 mutant nematodes in the NML25, NML50 and NML100 groups were (42.7±0.7d), (45.1±0.7d) and (44.2±0.8d), respectively, which were -0.5% (P>0.05), 5.06% (P>0.05) and 3.01% (P>0.05) longer than that in the DMSO group (42.9±0.8d). Fig. 9and Table 2), that is, compared with the DMSO control group, there was no significant difference in the average lifespan of daf-2 mutant nematodes in the NML25, NML50 and NML100 administration groups. This shows that NML has no significant effect on the lifespan of daf-2 mutant nematodes. It can be seen that NML prolongs the lifespan of nematodes depends on the IIS signal transduction pathway, and the daf-2 gene is a key factor in the NML life extension pathway.

[0121] Table 2: Effects of NML on the lifespan of daf-2 mutant nematodes

[0122] Group Number of insects Average life span (days) Maximum lifespan (days) Median survival time (days) Extended life span percentage DMSO 218 43.16±0.69 62 44 - NML25 205 <![CDATA[42.57±0.67 n.s. ]]> 63 43 -1.37% NML50 225 <![CDATA[44.44±0.60 n.s. ]]> 64 45 2.99% NML100 215 <![CDATA[43.79±0.68 n.s. ]]> 64 45 1.46%

[0123] Note: The results are expressed as mean ± standard error, N represents the number of samples in each group; compared with the control group (DMSO), ns means no significant difference.

[0124] Effect of NML on the lifespan of daf-16 mutant nematodes

[0125] Like the daf-2 gene, the daf-16 gene is also an important factor in regulating life span in the IIS signaling pathway, and its expression level can reflect the level of life span regulation. Therefore, a life span experiment was also performed on the daf-16 mutant nematode, and the method of the life span experiment was the same as in Example 1. The results showed that the average survival period (12.44±0.24d) of the daf-16 mutant nematode in the DMSO control group was significantly shorter than that of the N2 nematode (16.3±0.3d), and the maximum survival period (23d) and the median survival period (12d) were significantly shorter than those of the N2 nematode (25d and 15d) (Table 3 and Table 1), indicating that the mutant model is stable. The average survival time of daf-16 mutant nematodes in the NML25, NML50 and NML100 treatment groups were (12.23±0.25d), (12.50±0.22d) and (12.81±0.23d), respectively, which were -1.66% (P>0.05), 0.46% (P>0.05) and 2.98% (P>0.05) longer than those in the DMSO control group (12.44±0.24d). Fig.10 and Table 3). That is, compared with the DMSO control group, there was no significant difference in the average lifespan of daf-16 mutant nematodes in the NML25, NML50 and NML100 administration groups. It can be seen that the mechanism by which NML prolongs the lifespan of nematodes is achieved by regulating the downstream daf-16 gene through the IIS pathway.

[0126] Table 3: Effects of NML on the lifespan of daf-16 mutant nematodes

[0127] Group Number of insects Average life span (days) Maximum lifespan (days) Median survival time (days) Extended life span percentage DMSO 198 12.44±0.24 23 12 - NML25 208 <![CDATA[12.23±0.25 n.s. ]]> 23 12 -1.66% NML50 207 <![CDATA[12.50±0.22 n.s. ]]> 24 12 0.46% NML100 197 <![CDATA[12.81±0.23 n.s. ]]> 24 12 2.98%

[0128] Effect of NML on DAF-16 nuclear localization

[0129] The results of NML's experiment on the life span of daf-16 mutant nematodes suggest that the mechanism by which NML extends the life span of nematodes may be achieved by regulating the downstream daf-16 gene through the IIS pathway. Therefore, this experiment used the transgenic worm strain daf-16p::daf-16::GFP (purchased from the National Bioresource Project of Japan) to observe and analyze the nuclear localization of DAF-16. In this worm strain, the expression of DAF16 and GFP fusion protein is driven by the daf-16 promoter. The localization state of DAF-16 in cells is generally divided into three types: distributed in the cytoplasm (cytosolic, that is, the fluorescence signal of daf-16::GFP is diffusely distributed in the cytoplasm), distributed in the nucleus (nuclear, that is, the fluorescence signal of daf-16::GFP is dotted in the nucleus from head to tail in the nematode body), and intermediate state (intermediate, referring to the fluorescence signal of daf-16::GFP being partly located in the nucleus and the other part in the cytoplasm). The daf-16P::daf-16::GFP nematodes were observed under a confocal microscope (Leica SP8, Leica Mikroskopie Systeme AG) from the time of administration in the L4 stage to the end of egg laying, and fluorescent images were collected. Based on the fluorescent images, the number of cells in each nematode in which the daf-16::GFP signal was localized in the cell nucleus was counted. Fig.11 As shown in a and b, the average number of cells with daf-16::GFP signal nuclear localization in the NML50 group (17.80±1.47 cells / nematode) was significantly higher than that in the DMSO control group (7.90±1.50 cells / nematode) (P<0.001). The results suggest that NML can significantly promote the migration of DAF-16 into the nucleus, and further confirm that the life-extending effect of NML on nematodes depends on the activity of DAF-16.

[0130] Example 4: Experiment on the detoxification ability of Nomilin against nematodes

[0131] In order to explore whether NML administration can improve the resistance of nematodes to exogenous compounds, the following experimental plan was designed:

[0132] 4.1. Experiment on the resistance of N2 nematodes to different doses of exogenous compounds after administration of NML50:

[0133] (1) Preparation and storage of compound stock solutions:

[0134] Chloroquine (purchased from Sane Chemical Technology (Shanghai) Co., Ltd., CAS#54-05-7, hereinafter referred to as CQ) 50 mM stock solution: weigh 15.99 mg CQ and add 1 mL DMSO solvent, vortex until completely dissolved;

[0135] Colchicine (purchased from Yuanye Biotechnology Co., Ltd., CAS#64-86-8, hereinafter referred to as CC) 50 mM stock solution: weigh 19.97 mg CC and add 1 mL DMSO solvent, vortex until completely dissolved;

[0136] Paraquat dichloride (purchased from Thermo Fisher Scientific (China) Co., Ltd., hereinafter referred to as PQ) 200 mM stock solution: weigh 43.65 mg PQ and add 1 mL M9 buffer, vortex until completely dissolved;

[0137] Methylmercury chloride (MeHgCl, purchased from Dr. Ehrenstorfer GmbH, CAS#115-09-3) 50 mM stock solution: 12.55 mg MeHgCl was weighed and added to 1 mL DMSO solvent, and ultrasonicated until completely dissolved.

[0138] (2) Preparation of toxicity test compound system:

[0139] CQ and CC: dilute the 50 mM stock solution with S-buffer to 0 (i.e., S-buffer only), 1, 2, and 4 mM;

[0140] PQ: 200 mM stock solution was diluted with M9 buffer to 0 (i.e., M9 buffer only), 4, 20, and 100 mM;

[0141] MeHgCl: dilute the 50 mM stock solution with S-buffer to 0 (i.e., S-buffer only), 0.5, 2, and 10 μM;

[0142] Then, DMSO (control group) or NML50 (drug administration group) was added to each dose dilution solution at a concentration ratio of 1:1000.

[0143] (3) Sample addition:

[0144] Take a 96-well plate. Two compounds can be used for detoxification experiments on each plate at the same time. The compound system, sample volume, nematode strain and group added to each well are shown in Table 4:

[0145] Table 4: Plate loading scheme for toxicity experiments of two compounds

[0146]

[0147]

[0148] The toxicity experiments of the other two compounds (PQ and MeHgCl) refer to this sample addition scheme. After adding the samples, the 96-well plate was placed in a 20°C biochemical incubator, and the time of placement was recorded as 0;

[0149] (4) Data Recording:

[0150] The PQ and MeHgCl plates were taken out from the biochemical incubator after 4 h and 10 h, respectively, and the number of dead nematodes in the control group and the drug-treated group was recorded.

[0151] The toxicity test plates of CQ and CC were taken out after 24 hours, and the number of dead nematodes in the control group and the drug-treated group was recorded.

[0152] The time when the toxicity experiments of the above compounds were terminated was obtained from the results of the preliminary experiments. The criterion for judging the death of nematodes refers to the lifespan experiment in Example 1.

[0153] 4.2. Experiment on the resistance of N2 nematodes to exogenous compounds after administration of different doses of NML:

[0154] The NML doses used in this experiment were: 0, 6, 12, 25 and 50 mM.

[0155] (1) Preparation of toxicity test compound system:

[0156] CQ and CC: dilute 50 mM stock solution to 4 mM with S-buffer;

[0157] PQ: dilute 200 mM stock solution to 20 mM with M9 buffer;

[0158] MeHgCl: dilute 50 mM stock solution to 2 μM using S-buffer;

[0159] Then, DMSO or NML6, 12, 25, 50 administration groups were added to the dilution solution at a concentration of 1:1000.

[0160] (2) Sample addition:

[0161] Take a 96-well plate. Two compounds can be tested for toxicity simultaneously on each plate. The compound system, sample volume, nematode strain and group added to each well are shown in Table 5:

[0162] Table 5: Plate loading scheme for toxicity experiments of two compounds (nematodes given different doses of NML)

[0163] Hole No. Compound system (100 μL per well) Nematodes (8 wells x 6 per well) A1-H1 4mM CQ+DMSO Synchronized N2 nematodes were fed OP50 plus DMSO from L1 to L4 A2-H2 4mM CQ+NML6 Synchronized N2 nematodes fed with OP50 plus NML6 from L1 to L4 A3-H3 4mM CQ+NML12 Synchronized N2 nematodes fed with OP50 plus NML12 from L1 to L4 A4-H4 4mM CQ+NML25 Synchronized N2 nematodes fed with OP50 plus NML25 from L1 to L4 A5-H5 4mM CQ+NML50 Synchronized N2 nematodes fed with OP50 plus NML50 from L1-L4 stage A6-H6 4mM CC+DMSO Synchronized N2 nematodes were fed OP50 plus DMSO from L1 to L4 A7-H7 4mM CC+NML6 Synchronized N2 nematodes fed with OP50 plus NML6 from L1 to L4 A8-H8 4mM CC+NML12 Synchronized N2 nematodes fed with OP50 plus NML12 from L1 to L4 A9-H9 4mM CC+NML25 Synchronized N2 nematodes fed with OP50 plus NML25 from L1 to L4 A10-H10 4mM CC+NML50 Synchronized N2 nematodes fed with OP50 plus NML50 from L1-L4 stage

[0164] The toxicity experiments of the other two compounds (PQ and MeHgCl) and nematodes after administration of different doses of NML were carried out according to this loading scheme. After loading, the 96-well plate was placed in a biochemical incubator at 20°C, and the time of placement was recorded as 0;

[0165] (3) Data Recording:

[0166] The method is the same as point (4) of 1.1 of Example 4.

[0167] 4.3. Changes in nematode resistance to different compounds after NML administration

[0168] This experiment tested the resistance of N2 nematodes to different doses (0 mM, 1 mM, 2 mM and 4 mM) of chloroquine and colchicine after synchronization and administration of NML50 from L1 to L4 (see Fig.12 a and c) and the resistance of N2 nematodes to the same dose (4 mM) of chloroquine and colchicine after synchronization and administration of different doses (0 μM, 6 μM, 12 μM, 25 μM and 50 μM) of NML from L1 to L4 (see Fig.12 b and d). Fig.12 As shown in a and c, compared with the DMSO control group, the resistance of N2 nematodes in the NML50 group to 2mM and 4mM chloroquine and 4mM colchicine was significantly increased (p < 0.05, p < 0.001 and p < 0.01, respectively). Fig.12 The results of b and d show that the resistance of N2 nematodes to 4mM chloroquine and 4mM colchicine in the 25μM and 50μM NML administration groups is also significantly increased compared with the 0μM NML control group (p<0.01, p<0.001, p<0.05 and p<0.001, respectively). This shows that the administration of 25μM and 50μM NML can significantly increase the resistance of N2 nematodes to the exogenous compounds chloroquine and colchicine.

[0169] In addition to chloroquine and colchicine, N2 nematodes administered NML50 from the L1-L4 stage after synchronization were tested for resistance to different doses (0 mM, 4 mM, 20 mM and 100 mM) of paraquat dichloride and (0 μM, 0.5 μM, 2 μM and 10 μM) of methylmercuric chloride (see Fig.13 a and c) and the resistance of N2 nematodes to the same dose of paraquat dichloride (20 mM) and methylmercury chloride (2 μM) after synchronization and administration of different doses (0 μM, 6 μM, 12 μM, 25 μM and 50 μM) of NML from L1 to L4 (see Fig.13 b and d). Fig.13 The results of a and c show that compared with the DMSO control group, the resistance of N2 nematodes in the NML50-treated group to 20mM and 100mM paraquat dichloride and 0.5μM and 2μM methylmercuric chloride was significantly increased (all p < 0.001). Fig.13As shown in b and d, the resistance of N2 nematodes to 20mM paraquat dichloride (all p<0.001) and to 2μM methylmercuric chloride (p<0.01) in NML groups of different doses was significantly increased compared with the 0μM NML control group. This indicates that the administration of different doses (6μM, 12μM, 25μM and 50μM) of NML can significantly enhance the resistance of N2 nematodes to paraquat dichloride, and 50μM NML can also increase the resistance of N2 nematodes to methylmercuric chloride.

[0170] Example 5: Pharmacodynamic evaluation of NML in improving the healthy life span of D-galactose-induced aging mice

[0171] 5.1. Experimental groups and drug administration

[0172] Experimental animals: 60 8-week-old C57BL / 6J mice (purchased from Slack), clean grade, weighing (18±2) g, half male and half female, given normal feed and adaptively raised in the animal room for 1 week.

[0173] Mouse grouping and drug administration: After one week of adaptation, the mice were randomly divided into three groups according to their body weight, namely, normal control group, D-galactose aging group, and D-galactose aging group + NML intervention group, with half male and half female in each group. Except for the control group, the other two groups used galactose subcutaneous injection to prepare the mouse aging model, that is, 125 mg / kg of D-galactose was subcutaneously injected into the back of the neck at regular intervals every day. While modeling, the NML intervention group was fed with mixed drug feed prepared in advance. After 6 consecutive weeks, the aging indicators were detected, and the weight, coat color, mental state, and behavior of the mice were observed.

[0174] Effects of NML on mouse behavior

[0175] (1) Pole climbing test: The pole climbing test device consists of a wooden stick (1 cm in diameter, 52 cm in height) and a wooden ball (2.5 cm in diameter) on top of the stick. The device is wrapped with medical tape to prevent the mouse from slipping. During the experiment, the mouse is placed head down with its hind paws on the ball, and the time it takes to climb down from the stick (T-climbing) is recorded. Each mouse is tested twice, and the average value is taken for statistics. During this process, when the mouse climbs from the pole to the cage for more than 20 s, T-climbing is recorded as 20 s.

[0176] (2) Balance beam test: Measure the coordination and balance of mice. Place a cylindrical wooden stick (1 cm in diameter, 50 cm in length) wrapped with medical tape above the cage. Place the mouse on one side of the stick and record the time it takes for the mouse to reach the other end of the stick (successful arrival is when the front paw touches the edge of the cage). Each mouse undergoes two experiments, with an interval of 30 minutes between experiments. When the mouse takes more than 30 seconds to walk from one side of the stick to the other side, the elapsed time is recorded as 30 seconds.

[0177] D-galactose induced a decrease in the motor ability of mice, including the time to climb the pole and the time to pass the balance beam. Mice treated with nomilin significantly improved the time to climb the pole and the time to pass the balance beam, indicating that nomilin significantly improved the aging-related motor decline in mice ( Fig.16 A and B).

[0178] 5.3. NML delays inflammatory response in liver and brain of D-galactose-induced aging mice

[0179] Sample collection and preparation: After the behavioral study, blood was collected from the mouse heart, and the whole blood of the mouse was centrifuged at 3000 rpm for 10 minutes. The upper serum was collected, packaged and stored in a -80℃ refrigerator. Half of the mouse liver and whole brain were quickly removed, fixed with formaldehyde, embedded in paraffin, sliced ​​at 5μm, stained with HE, sealed with neutral gum, observed under a microscope and photographed. The liver and heart of the other half of the mice were quickly frozen in liquid nitrogen and then stored in a -80℃ refrigerator for use; after the whole brain was removed, the cortex, hippocampus and other brain tissues were separated, and also frozen in liquid nitrogen, and stored in a -80℃ refrigerator for use. D-galactose induced inflammatory cell infiltration in the mouse liver. HE staining showed that nomilin reduced the inflammatory cell infiltration in the mouse liver ( Fig.14 D-galactose increased the apoptosis of CA1, CA3 and dentate gyrus neurons in the mouse hippocampus, while nomilin-treated mice showed a significant decrease in hippocampal apoptotic cells ( Fig.15 ).

[0180] 5.4. Effect of NML on delaying the expression of aging-related genes in mice

[0181] Mouse tissues were cut into the same size, total RNA was extracted from the tissues, and reverse transcription kit was used to reverse transcribe RNA into cDNA. The q-PCR method was used to detect inflammation-related genes including Mcp1, IL-1β, Tnf-α, and Nlrp3; antioxidant enzyme-related genes Nrf-2, Keap1, Nqo1, etc.; PXR downstream detoxification enzyme genes including the first phase detoxification enzyme CYP450 enzyme system genes and the second phase detoxification enzyme gene Gstal were detected. Nomilin inhibited the expression of IL-1β and Ho-1 in the liver of aged mice induced by D-galactose, and increased the expression of Nrf2 and Sod-1 ( Fig.18 Meanwhile, nomilin increased the expression of detoxification genes Cyp3a11 / 13, Cyp2d22, Cyp2e1, Cyp8b1, Cyp51, Gsta1 / 2, Por, and Tyw1 ( Fig.17 , Ctrl is control, D-gal is D-galactose), indicating that the detoxification ability of mice was increased after the administration of nomilin.

[0182] The above examples show that Nomilin has the following effects:

[0183] 1. Nomilin prolongs the average lifespan and maximum lifespan of wild-type N2 nematodes, and the lifespan-extending effect of 50 and 100 μM Nomilin is the most significant.

[0184] 2. The activity of nematodes, such as swallowing frequency, head swinging frequency and body bending frequency, decreases with age. Nomilin can significantly enhance the swallowing frequency, head swinging frequency and body bending frequency of nematodes that decrease with aging.

[0185] 3. Nomilin can also significantly reduce the deposition of lipofuscin caused by aging in wild-type nematodes.

[0186] 4. Nomilin can prolong the survival time of nematodes under conditions of acute heat stress at 35°C and oxidative stress caused by 0.5‰ hydrogen peroxide, and increase the nematodes' resistance to heat shock and oxidative stress.

[0187] 5. Nomilin can promote the nuclear translocation and transcriptional activity of longevity-related DAF-16 and regulate the expression of downstream stress resistance-related genes.

[0188] 6. Toxicity experiments showed that nomilin could increase the resistance of wild-type N2 nematodes to exogenous compounds such as chloroquine, colchicine, paraquat dichloride and methylmercury chloride.

[0189] 7. Nomilin delays the healthy lifespan of D-galactose-induced aging mice, improves degenerative changes in the heart, liver and brain, and enhances the motor capacity of mice.

[0190] 8. Nomilin can inhibit the expression of genes related to liver inflammation induced by D-galactose in aged mice and increase the expression of genes related to anti-oxidative stress and detoxification.

Claims

1. Use of a compound as shown in the following formula or a composition containing the compound in the preparation of an anti-aging drug; ; The composition further comprises a pharmaceutically acceptable carrier and / or excipient.

2. The use according to claim 1, characterized in that The symptoms of aging are selected from decreased mobility, increased lipofuscin deposition, decreased liver resistance to oxidative stress and decreased detoxification capacity; And / or, in the composition, the content of the compound is 20-150 μM.

3. The use according to claim 2, characterized in that In the composition, the content of the compound is 25-120 μM.

4. The use according to claim 3, characterized in that In the composition, the content of the compound is 50-100 μM.